TY  - CHAP
M1  - Book, Section
TI  - Autophagy and Human Genetic Disease
A1  - Underwood, Benjamin R.
A1  - Massey, Dunecan C. O.
A1  - Rubinsztein, David C.
A2  - Valle, David L.
A2  - Antonarakis, Stylianos
A2  - Ballabio, Andrea
A2  - Beaudet, Arthur L.
A2  - Mitchell, Grant A.
Y1  - 2019
N1  - 10.1036/ommbid.186
T2  - The Online Metabolic and Molecular Bases of Inherited Disease
AB  - Autophagy  is  an  intracellular  bulk  degradation  system.The  genetics,  signalling  and  regulation  of  autophagy  have  been  a  major  focus  of  research  for  the  last  decade  and  consequently  these  are  increasingly  well  understood.Defects  in  autophagy  are  now  known  to  underpin  a  number  of  Mendelian  human  genetic  diseases  including  multiple  sulfatase  deficiency,  mucopolysaccharidosis  type  IIIA,  X-linked  myopathy  with  excessive  autophagy,  Danon  disease,  Pompe  disease,  and  some  forms  of  familial  frontotemporal  lobar  degeneration.  Autophagy  may  also  be  involved  in  familial  forms  of  Parkinson’s  disease.  Furthermore,  genome  wide  association  studies  are  identifying  autophagy  as  an  important  process  underlying  risk  alleles  for  more  complex  polygenic  diseases,  such  as  Crohn’s  disease.Autophagy  can  be  induced  or  inhibited  by  a  number  of  physiological  and  pharmacological  stimuli.Manipulation  of  autophagy  with  drugs  is  a  promising  therapeutic  strategy  for  a  number  of  human  genetic  diseases  characterised  by  aggregation  of  abnormal  proteins.  These  diseases  include  polyglutamine  diseases,  such  as  Huntington’s  disease  and  some  familial  forms  of  frontotemporal  lobar  degeneration  and  Parkinson’s  disease.  This  is  important,  as  there  are  currently  no  treatments  which  modify  the  rate  of  neurodegeneration  in  these  conditions.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
M3  - doi: 10.1036/ommbid.186
Y2  - 2024/04/24
UR  - ommbid.mhmedical.com/content.aspx?aid=1181467317
ER  -